Kansas City, Kansas 66160


Purpose:

The purpose of this study is to determine if Rifaximin decreases serum and urine levels of bacterial byproducts and inflammatory markers in patients with chronic kidney disease and to evaluate changes in the bacterial content of the stool from these individuals.


Criteria:

Inclusion Criteria: - Chronic kidney disease with eGFR ≤ 39 ml/min/1.73m2 Exclusion Criteria: - Patients with normal renal function or those with less advanced kidney disease - Inability or unwillingness to provide consent - Patients undergoing hemodialysis or peritoneal dialysis therapy or those who have undergone organ transplant - Patients who may be pregnant - Hemodynamically unstable patients - Patients with liver failure, pancreatic insufficiency, or inflammatory bowel disease - Patients with ongoing or recent infection and those with history of C-diff infection - Patients with abnormal bowel structure secondary to surgical or anatomic variations - Patients on certain medications including immunosuppressants, antidiarrheal agents, bile acid sequestrants and current or recent (within the last 3 months) use of antibiotics


NCT ID:

NCT02342639


Primary Contact:

Principal Investigator
Jason Stubbs, MD
University of Kansas Medical Center

Cassandra Kimber, D.O.
Email: ckimber@kumc.edu


Backup Contact:

N/A


Location Contact:

Kansas City, Kansas 66160
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.